TY - JOUR
T1 - Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV
AU - Toyoda, Hidenori
AU - Tada, Toshifumi
AU - Tachi, Yoshihiko
AU - Hirai, Takanori
AU - Yasuda, Satoshi
AU - Honda, Takashi
AU - Hayashi, Kazuhiko
AU - Ishigami, Masatoshi
AU - Goto, Hidemi
AU - Kumada, Takashi
N1 - Publisher Copyright:
© 2017 International Medical Press.
PY - 2017
Y1 - 2017
N2 - Background: Hepatocellular carcinoma (HCC) in patients with chronic hepatitis C can develop after sustained virological response (SVR) to antiviral therapy for HCV, that is, the eradication of HCV, and effective surveillance systems for HCC should be established for this population. We retrospectively evaluated the utility of three laboratory liver fibrosis indices (aspartate aminotransferase-platelet ratio index [APRI], FIB-4 index and Forns index) for identifying patients at low risk of HCC development after SVR, for whom the termination of surveillance for HCC can be considered. Methods: APRI, FIB-4 index and Forns index scores were calculated based on laboratory data prior to anti- HCV therapy and at 24 weeks after the end of anti-HCV therapy (SVR24) in 522 patients with SVR who continued surveillance for HCC after SVR. The associations between HCC development and laboratory indices at both points were analysed. Results: Twenty-one patients developed HCC after SVR during 2.3-24.4 years follow-up. Whereas HCC developed even in patients with low APRI or FIB-4 index scores, no patients with low Forns index scores developed HCC after SVR. These results were confirmed in a separate cohort of 309 patients who achieved SVR (HCC developed in 17 patients during 1.7-21.6 years follow-up). Conclusions: Forns index, especially assessed prior to anti-HCV therapy, was a useful laboratory liver fibrosis index for identifying patients at low likelihood of HCC after SVR. This index may be used as one of indicators to consider the termination of surveillance for HCC after the eradication of HCV.
AB - Background: Hepatocellular carcinoma (HCC) in patients with chronic hepatitis C can develop after sustained virological response (SVR) to antiviral therapy for HCV, that is, the eradication of HCV, and effective surveillance systems for HCC should be established for this population. We retrospectively evaluated the utility of three laboratory liver fibrosis indices (aspartate aminotransferase-platelet ratio index [APRI], FIB-4 index and Forns index) for identifying patients at low risk of HCC development after SVR, for whom the termination of surveillance for HCC can be considered. Methods: APRI, FIB-4 index and Forns index scores were calculated based on laboratory data prior to anti- HCV therapy and at 24 weeks after the end of anti-HCV therapy (SVR24) in 522 patients with SVR who continued surveillance for HCC after SVR. The associations between HCC development and laboratory indices at both points were analysed. Results: Twenty-one patients developed HCC after SVR during 2.3-24.4 years follow-up. Whereas HCC developed even in patients with low APRI or FIB-4 index scores, no patients with low Forns index scores developed HCC after SVR. These results were confirmed in a separate cohort of 309 patients who achieved SVR (HCC developed in 17 patients during 1.7-21.6 years follow-up). Conclusions: Forns index, especially assessed prior to anti-HCV therapy, was a useful laboratory liver fibrosis index for identifying patients at low likelihood of HCC after SVR. This index may be used as one of indicators to consider the termination of surveillance for HCC after the eradication of HCV.
UR - http://www.scopus.com/inward/record.url?scp=85021712720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021712720&partnerID=8YFLogxK
U2 - 10.3851/IMP3081
DO - 10.3851/IMP3081
M3 - Article
C2 - 27586087
AN - SCOPUS:85021712720
SN - 1359-6535
VL - 22
SP - 185
EP - 193
JO - Antiviral Therapy
JF - Antiviral Therapy
IS - 3
ER -